Critiquing: Doctor accused of selling false hope to families (USA TODAY NEWS, NATION, Liz Szabo, USA TODAY)

I gave Liz Szabo and USA TODAY the chance to act like a Spike Lee joint and “Do the Right Thing”, the same day their article came out [1]

I gave them the opportunity to prove that their article was a legitimate piece of journalism with some semblance of integrity, and NOT just akin to one of “The Skeptics™ phoned-in “rubber-stamped” yellow journalism hit pieces

Instead, it seems that Liz Szabo and / or USA TODAY decided to act as if they had rolled a Spike Lee joint

I sent an e-mail with 2 editorial corrections, and only one (correcting Lisa Merritt’s comment
link from taking the reader to the 1999 Mayo Clinic report instead of to her comments), was corrected [2]

The 2nd correction which they #FAILED to do, earns them well deserved INSOLENCE
The article claims:
Burzynski, 70, calls his drugs “antineoplastons” and says he has given them to more than 8,000 patients since 1977.”

However, if you select the “8,000 patients” link, the referenced page does NOT indicate that at all [2]

It advises:
“That same year, Dr. Burzynski founded his clinic in Houston where he’s since treated over 8,000 patients.” [3]

Nowhere does it indicate that he “treated 8,000 patients” with antineoplastons

The question that Liz Szabo and USA TODAY should answer, is:

1. Who is your “fact-checker”, and
2. are they smarter than a 5th grader ?
In fact, Burzynski’s 2002 Securities and Exchange Commission (SEC) filing advises:

” … in 1997, his medical practice was expanded to include traditional cancer treatment options such as chemotherapy, gene targeted therapy, immunotherapy and hormonal therapy in response to FDA requirements that cancer patients utilize more traditional cancer treatment options in order to be eligible to participate in the Company’s Antineoplaston clinical trials” [4]
The article continues:
“Individual success stories can be misleading, said Arthur Caplan, a professor and head of the division of bioethics at NYU Langone Medical Center”
The question Arthur Caplan should be asking is:

Why has the United States Food and Drug Administration required Burzynski’s clinical trial patients to fail conventional therapies; such as surgery, chemotherapy, and radiation, BEFORE they are allowed to be treated with antineoplaston therapy ?

If the F.D.A. did NOT impose these restrictions upon Burzynski’s clinical trials, then the question Arthur Caplan raises would be moot
The article quotes Dr. Jan Buckner as saying:
“When I hear a story that is way out of the norm, the first question I ask is,

‘OK, is the diagnosis even correct?‘ ”

Buckner said”

“If the diagnosis wasn’t right to start with, it doesn’t matter what the treatment was.”

“Brain tumors are notoriously difficult to diagnose, Buckner says”

“When dealing with rare brain cancer, doctors may disagree about how to interpret imaging results up to 40% of the time”
I wonder if Dr. Jan Buckner would agree with David Gorski; who is a BREAST cancer oncology specialist, and NOT a BRAIN cancer oncology specialist, who has the presumptiveness to speculate that 3 different medical opinions could have misdiagnosed Tori Moreno in August 1998; who was diagnosed with a very large tumor, about 3 inches in the largest diameter and located in the brain stem, which was too risky for surgery, and about which her parents were told by ALL 3, that Tori’s brain cancer was fatal and, she would die in a few days or at the most, 2-6 weeks, and that there was nothing that could be done, and was finally put on Burzynski’s antineoplaston therapy in October, when she was about 3 ½ months old, and in such condition that they were afraid that she might die at any time, David H. Gorski, M.D., Ph.D., FACS; who claims, “I do know cancer science” , has the audacity, because of his “book learnin'” has the temerity to postulate his “science-based medicine theory” that Miller’s Children at Long Beach Memorial misdiagnosed Tori Moreno’s inoperable stage 4 BSG

David Gorski has the gall to profer that City of Hope misdiagnosed Tori Moreno’s inoperable stage 4 brain stem glioma

David Gorski has the chutzpah to pontificate that Dr. Fred Epstein in New York misdiagnosed Tori Moreno’s inoperable stage IV brainstem glioma [5]
The article then quotes Peter Adamson, chair of the Children’s Oncology Group:
“But these therapies may have delayed benefits, taking weeks or months to shrink a tumor

“So patients treated by Burzynski may credit him for their progress, just because he was the last doctor to treat them, says Peter Adamson, chair of the Children’s Oncology Group, an NCI-supported research network that conducts clinical trials in pediatric cancer

Conventional cancer treatment can also cause tumors to swell temporarily, due to inflammation

“A patient who isn’t familiar with this phenomenon may assume her tumor is growing

“When that swelling subsides, patients may assume it’s because of Burzynski, Adamson says”
This is laughable

In support of this “phenomenon” , the article provides a link to a Canadian web-site [6]

The site posits:
“RT/TMZ is now widely practiced and the standard of care for appropriately selected patients, we are learning more about the consequences of RT/TMZ”

“One phenomena, termed Pseudo-Progression (psPD)…”
The problem is that this only applies to “Glioblastoma Multiforme (GBM)”, and the article provides NO proof whatsoever, that any of Burzynski’s “Glioblastoma Multiforme (GBM)” patients have taken “RT/TMZ”
Additionally, the site cites the reference as:

Sanghera, Perry, Sahgal, et al., “Sunnybrook Health Sciences Odette Cancer Centre” (in press, Canadian Journal of Neuroscience)

(“In press” refers to journal articles which have been accepted for publication, but have not yet been published)

However, the journal article in question was published 1/2010, so it has NOT been “in press” for over 3 years and 7 months [7]

Get your act together, aye, Canada !
The article rants and raves on and on about FDA inspection reports from as far back as 1998, but at least they did quote Richard A. Jaffe:

“In Burzynski’s defense, Jaffe notes that inspection reports represent preliminary findings

“The FDA has not yet issued final conclusions”
The article posts this ridiculous claim:
“Yet the National Cancer Institute says there is no evidence that Burzynski has cured a single patient, or even helped one live longer
That’s NOT what this seems to suggest [8]
Then the article quotes pediatric oncologist Peter Adamson, a professor of pediatrics and pharmacology at Children’s Hospital of Philadelphia, in what will no doubt soon be known as a “classic”:
“He’s a snake oil salesman,” says pediatric oncologist Peter Adamson, a professor of pediatrics and pharmacology at Children’s Hospital of Philadelphia”
All I’d like to know is, which rock did this clown crawl out from under ?

Dr. Adamson, please advise which “snake oil” has been granted Orphan Drug Designation (“ODD”) from the United States Food and Drug Administration [9], and which “snake oil” has been approved for, and used in, phase III clinical trials ? [10]
Q: Is it, it the phase 2 trial is finished ?

A: “Mhmm”

Q: but they’re still accepting people ?

A: “Yeah”

Q: on more like a special ?

A: Special basis, and, um, sometimes compassionate grounds

A: “(compassion exception)”

A: “Uh, exceptions

Q: That’s normal ?

A: “Yes”

A: “(Yes I guess it is a funding issue ?)”

Q: Right

A: “(Like FDA, during the 2nd phase of clinical trials they found the data to be, real, real one, and they gave him the ok to go for 3rd phase of clinical trials, but just to go through this process you would probably need $100,000)”



Oh, wait !!

Dr. Adamson, when you say “snake oil”, I take it you are referring to the low-dose chemotherapy that Burzynski uses ?

Dr. Adamson, do you know what a “hack” is ?
In regards to the Merritt’s, the article has:
“The couple say that Burzynski misled them about the type of treatment that would be offered, as well as the cost”

My questions about the Merritt’s are:

1. Where is their complaint to the Texas Medical Board ?

2. Where is their lawsuit ? Couldn’t they find an attorney to take their case pro bono ?
The article continues:
“Yet even Jaffe has acknowledged that the trialnow in its 17th year — was more about politics than science”

“In his 2008 memoirs, Galileo’s Lawyer, Jaffe called it “a joke.”

“”It was all an artifice, a vehicle we and the FDA created to legally give the patients Burzynski’s treatment,” Jaffe said
What Liz Szabo and her friends at USA TODAY fail to let the readers know, is that this only applied to one trial:
Burzynski’s lawyer is obviously referring to the CAN-1 clinical trial mentioned in Burzynski’s 11/25/1997 Securities and Exchange Commission (SEC) filing [11]
One trial that is retrospective is CAN-1 Clinical Trial


133 patients
Clinical trial of patients treated by Dr. Burzynski through 2/23/1996
FDA has indicated it will not accept data generated by this trial since it was not a wholly prospective one
The article continues in the same vein:
“In an interview, Burzynski said developing new drugs is complex and takes time

“Yet the FDA has approved 108 cancer drugs since Burzynski began his trial”
Ms. Szabo and “pals” conveniently “forgets” to educate their audience that Burzynski was using Fleming’s One-sample multiple testing procedure for phase II clinical trials [13], which requires that if the 1st 20 patients meet certain criteria, 20 additional patients are added [14]
“Well, we cannot publish until the time is right” (laughs)


“If you would like to publish the results of, of a
10 year survival, for instance”


“Which we have
Nobody has over 10 year survival in
malignant brain tumor, but we do, and if you like to do it right, it takes time to prepare it, and that’s what we do now
What we publish so far
We publish numerous, uh, publications which were, interim reports when we are still continuing clinical trials
Now we are preparing, a number of publications for final reports
Then Fran Visco, president of the National Breast Cancer Coalition makes an outlandish statement, which is quoted in the article:
“Fran Visco, president of the National Breast Cancer Coalition, describes the FDA’s tolerance of Burzynski as “outrageous.”

“They have put people at risk for a long time,” says Visco, an attorney and breast cancer survivor

“That’s completely unacceptable”

“How can anyone look at these facts and believe that there is a real clinical trial going on … rather than just using the FDA and the clinical trial system to make money?”
I have a suggestion for Ms. Visco

Take your hypocrisy and ask the American Cancer Society if they are still engaged in this kind of activity:

1. AMERICAN CANCER SOCIETY: More Interested In Accumulating Wealth Than Saving Lives [15]

2. National Cancer Institute and American Cancer Society: Criminal Indifference to Cancer Prevention and Conflicts of Interest [16]
Then, ask the American Cancer Society, why is it that 10 years ago, estimated breast cancer deaths were expected to be 39,800 (15%), and this year it was 39,620 (14%), which is ONLY 180 LESS than 10 years ago ?
Estimated Breast Cancer Deaths (Women)-USA
2013☝39,620 (14%)
2012👇39,510 (14%)
2011👇39,520 (15%)
2010👇39,840 (15%)
2009👇40,170 (15%)
2008☝40,480 (15%)
2007👇40,460 (15%)
2006☝40,970 (15%)
2005👇40,410 (15%)
2004☝40,110 (15%)
2003☝39,800 (15%)
39,600 (15%)
American Cancer Society Cancer Facts & Figures (2002-2013)
And then ask the American Cancer Society, why is it that 10 years ago, the estimated NEW breast cancer cases were expected to be 211,300 (32%), and this year it was 232,340 (29%), which is 21,340 MORE than it was 10 years ago ?
Estimated New Breast Cancer (Women) – USA
2013☝232,340 (29%)
2012👇226,870 (29%)
2011☝238,480 (30%)
2010☝207,090 (28%)
2009☝192,370 (27%)
2008☝182,460 (26%)

2007👇178,480 (26%)
2006☝212,920 (31%)
2005👇211,240 (32%)
2004☝215,900 (32%)
2003☝211,300 (32%)
_-_203,500 (31%)
American Cancer Society Cancer Facts & Figures (2002-2013)
And after that, ask Susan G. Komen how much is spent on legal action to protect her brand, compared to how much is spent on breast cancer research and prevention ?
Visco, the breast cancer advocate

“I do NOT know why it took YOU so long.”
The article continues with:
“Yet hypernatremia is one of antineoplastons’ most common side effects, known to doctors for two decades”
Yet, “The Skeptics™” refuse to discuss:
2/13/2013 – The frequency, cost, and clinical outcomes of hypernatremia in patients hospitalized to a comprehensive cancer center

Over 3 month period in 2006 re 3,446 patients, most of the hypernatremia (90 %) was acquired during hospital stay [19]

Division of Internal Medicine, UT MD Anderson Cancer Center, Houston, TX, USA

Department of General Internal Medicine, University of Texas MD Anderson Cancer Center

Division of Endocrinology, Mayo Clinic
9/1999 – The changing pattern of hypernatremia in hospitalized children [20]

Department of Pediatrics, Texas Children’s Hospital, Baylor College of Medicine, Houston, Texas, USA
So, after all that, my question for USA TODAY is, does Liz Szabo, Michael Stravato, Jerry Mosemak or Robert Hanashiro have a
journalism degree ?

Because if any of them do, the institution they obtained it from most be so proud of this piece of “fish wrap” you produced

Thank you, USA TODAY, for censoring my 18 comments

I guess you must be (“intellectual”) cowards

At least Forbes had the GRAPEFRUITS to post some of my comments
You’ve just been served, INSOLENTLY

















[1] – 11/15/2013 – USA TODAY NEWS, NATION
Doctor accused of selling false hope to families
Liz Szabo, USA TODAY
[2] – Mayo Clinic – 1999 – report: Lisa Merritt
[3] – 2012 – former Burzynski web-site screenshots, Pg 3 of 62;

Click to access burzynski_fdauntitled_promo_2012.pdf

[4] – 4/26/2013 – Burzynski: FDA requirements that cancer patients utilize more traditional cancer treatment options in order to be eligible to participate in the Company’s Antineoplaston CLINICAL TRIALS:
[5] – 11/14/2013 – Critiquing: Why we fight for patients (Why we fight your patience) TAM 2013, TAM2013, “The Amazing Meeting” 2013 #TAM2013
[6] – Phenomenon – Brain Tumour Foundation of Canada
[7] – Pseudoprogression following chemoradiotherapy for glioblastoma multiforme
Can J Neurol Sci. 2010 Jan;37(1):36-42
[8] – 9/19/2013 – Critiquing: National Cancer Institute (NCI) at the National Institutes of Health (NIH) CancerNet “fact sheet” :
[9] – FDA Orphan Drug Designation

Click to access PressRelease_12022008_BZYR(2).pdf

[10] – 11/7/2013Pete Cohen chats with Sonali Patil, Ph.D., Research Scientist at The Burzynski Clinic:
[11] – 7/9/2013 – Burzynski: The Original 72 Phase II Clinical Trials:
[12] – 8/21/2013 – Critiquing David H. Gorski, MD, PhD, FACS
[13] – 2003 – pg. 94

Click to access 960.pdf

[14] – 3/1982 – Biometrics 1982; 38: 143-51
[15] – 11/9/2013Pete Cohen chats with Dr. Stanislaw Burzynski – Interview #2:
[16] – AMERICAN CANCER SOCIETY: More Interested In Accumulating Wealth Than Saving Lives

Click to access acs.pdf

[17] – 9/11/2013 – National Cancer Institute and American Cancer Society: Criminal Indifference to Cancer Prevention and Conflicts of Interest:
[18] – 11/13/2013 – The War on Cancer (I don’t think it means, what you think it says it means) #Winning?
[19] – 4/24/2013 – Burzynski: HYPERNATREMIA:
[20] – 9/1999 – Pediatrics. 1999 Sep;104(3 Pt 1):435-9


Critiquing: Stanislaw Burzynski: On the arrogance of ignorance about cancer and targeted therapies

12/5/2012 Dr. David H. “Orac” Gorski, who claims to be a “researcher,” cooked up this gastronomically inedible MUD pie:

Stanislaw Burzynski: On the arrogance of ignorance about cancer and targeted therapies
and 3/11/2013 on #ScienceBasedMedicine . org:

Three myths about Stanislaw Burzynski and The Skeptics
5-6/2012 – Stanislaw R. Burzynski, MD, PhD: novel cancer research and the fight to prove its worth
Altern Ther Health Med. 2012 May-Jun;18(3):54-61.
Here we go again

Now here’s where we see the sheer arrogance, the sheer ignorance of the man:

Gorski quotes Dr Burzynski:

“I published the review article in a peer-reviewed journal almost 20 years ago on the principles of personalized gene-targeted therapy”

Gorski states:

“Curious as to just what the heck Burzynski was talking about here, I searched PubMed for this alleged review article”

“I couldn’t find it on PubMed”

“His only publications from the 1990s had nothing to do with cancer as a “genetic disease” or “personalized gene-targeted cancer therapy” and everything to do with antineoplastons”

“Perhaps Burzynski proposed this “revolutionary” new idea in a peer-reviewed article that’s not indexed in PubMed, but if he did I couldn’t find it using Google and Google Scholar”

“(In fact when I entered “Burznski” and “personalized gene therapy” into Google Scholar, I got the article containing the transcript of Burzynski’s interview that I’m discussing at the top of the hit list!)”

I had to choke back a rising bile in the back of my throat as I read this

I mean, seriously, such a combination of arrogance (Gorski apparently thinking that he was the kind of person who could intelligently conduct a PubMed, Google, and Google Scholar search on personalized therapy and targeting genes for cancer)

Gorski’s ignorance of the entire field of Internet searches is breathtaking!

Let’s put it this way

Gorski was in graduate school 20 years ago, and was not taught back then how to do an Internet search

Gorski fumes:

“There’s a term called “oncogene,” which describes genes that, when either mutated or too much is made, can result in cancer”

“Robert Huebner and George Todaro first coined it in 1969, and the first oncogene, src, was described in 1970, twenty years before Burzynski claims to have understood that cancer is a genetic disease”

“The first tumor suppressor gene, the retinoblastoma gene, was characterized in 1986, at least six years before Burzynski’s apparent “revelation” that cancer is a “genetic disease.””

As usual, Burzynski and Internet searching was way ahead of Gorski

One wonders if he has ever bothered to read:

Pg. 25

1987 – Liau, M.C., Szopa, M., Burzynski, B., Burzynski, S.R. Chemosurveillance: A novel concept of the natural defense mechanism against cancer. Drugs Exptl Clin Res 1987;13 (suppl 1):71-76.


Pg. 24

1997Burzynski. S.R. Antineoplastons. oncogenes and cancer. Anti-Aging Medical Therapeutics, Vol.1. Klatz RM.
Goldman R. (Ed). Health Quest Publication 1997; Marina del Rey, CA. USA.

Click to access burzynski_fdauntitled_promo_2012.pdf

But THAT would have required Gorski to do a search on the word “oncogene(s)”

Click to access UCM326633.pdf

former web-site screenshots:

Click to access burzynski_fdauntitled_promo_2012.pdf

Stanislaw Rajmund Burzynski Publications:

Burzynski: Oh, RATS!!!

After again showing how questionable the “research” of #ScienceBasedMedicine Dr. David H. “Orac” Gorski is:
and he is involved in the “War on Cancer,”(!!!) I decided to provide this more in-depth listing of Burzynski related scientific publications regarding animal, mice, and rat studies re: antineoplastons
1983 – Burzynski SR, Hendry LB, Mohabbat MO, et al. Purification of structure determination, synthesis and animal toxicity studies of antineoplaston A10. In: Proceedings of the 13th International Congress of Chemotherapy. Vienna, Austria; 1983:17, PS. 12.4 11-4.
1984 – Burzynski, S.R., Mohabbat MO, Burzynski B.
Animal toxicology studies on oral formulation of antineoplaston A10
Drugs Exptl Clin Res 1984;10:113-118
1984 – Lee, S.S., Mohabbat, M.O., Burzynski, S.R.
Tissue culture and animal toxicity studies of antineoplaston A2
Drugs Exptl Clin Res 1984;10:607-610
1985 – Lee, S.S., Mohabbat, M.O., Burzynski, S.R.
Tissue culture and acute animal toxicity studies of antineoplaston A2
Future Trends in Chemotherapy 1985;6:481-484
1986 – Burzynski, S., Mohabbat. M., Lee, S.
Preclinical studies of antineoplaston AS2-1 in mice with oral administration
Drugs Exptl Clin Res 1986;132
1986 – Burzynski, S. R., Mohabbat, M. O. , Le e, S. S. Pre clinical studies of antineoplaston AS2-1 and antineoplaston AS2-5
Drugs Exptl Clin Res 1986;12 (suppl1):11-16
Drugs Exp Clin Res. 1986;12 Suppl 1:11-6.
1986 – Ashraf, AQ., Liau, M.C., Mohabbat, M.O., Burzynski, S.R.
Preclinical studies of antineoplaston A10 injections.
Drugs Exptl Clin Res 1986;12 (suppl 1):37-45.
Drugs Exp Clin Res. 1986;12 Suppl 1:37-45.
1986 – Burzynski, S.R., Mohabbat M.O.
Chronic animal toxicity studies on antineoplaston A2.
Drugs Exptl Clin Res 1986;12 (suppl 1):73-75.
Drugs Exp Clin Res. 1986;12 Suppl 1:73-5.
1987 – Lee, S.S., Mohabbat, M.O., Burzynski, SR
In vitro cancer growth inhibition and animal toxicity studies of antineoplaston A3
Drugs Exptl Clin Res 1987;13 (suppl1):13-16
Drugs Exp Clin Res. 1987;13 Suppl 1:13-6.
1987 – Lee, S.S., Burzynski, S.R
Tissue culture and animal toxicity studies of antineoplaston A5
Drugs Exptl Clin Res 1987;13 (suppl 1):31-5.
Drugs Exp Clin Res. 1987;13 Suppl 1:31-5.
1987 – Ashraf AQ, Liau MC, Kampalath BN, et al. Pharmacokinetic study of radioactive antineoplaston A10 following oral administration in rats. Drugs Exptl Clin Res. 1987;13(suppl 1):45-50.
1988 – Ashraf, AQ., Kampalath, B.N., Burzynski, S.R
Pharmacokinetic analysis of antineoplaston A10 injections following intravenous administration in rats
Adv Exptl Clin Chemother 1988;6:33-39
7/20/1988 – Chemopreventive effect of antineoplaston A-10 on urethane-induced pulmonary neoplasm in mice
Nihon Gan Chiryo Gakkai Shi. 1988 Jul.20; 23 (7):1560-5
23(7):1560-5 (1988)
1/20/1990 – A-10 Injection – The anticancer effect of antineoplaston A-10 on human breast cancer serially transplanted to athymic mice
Nihon Gan Chiryo Gakkai Shi. 1990 Jan 20;25(1):1-5
1st Department of Surgery, Kurume University School of Medicine
The Anticancer Effect of Antineoplaston A-10 on Human Breast Cancer Serially Transplanted to Athymic Mice, Journal of the Japan Society for Cancer Therapy 25(1):1-5 (1990)
Hashimoto K, Koga T, Shintomi Y, Tanaka M, Kakegawa T, Tsuda H, Hara H.
1990 – Inhibitory effect of antineoplaston A-10 on breast cancer transplanted to athymic mice and human hepatocellular carcinoma cell lines. The members of Antineoplaston Study Group
Tsuda H (Japan) et al
Kurume Med J. 1990;37(2):97-104
Kurume Med J 37 (2):97-104 (1990)
Kurume University School of Medicine, Japan
Burzynski References: 1 – 8 and 11 – 14
The Kurume Medical Journal
J-STAGE, Japan Science and Technology Information Aggregator, Electronic
1991 – Inhibitory effect of orally administered antineoplaston A10 on the growth curve of human breast cancer transplanted to athymic mice
J Jpn Soc Cancer Ther 26:595-601, 1991
26:3:595-601:1991 03
Kurume Univ. School of Medicine
5/1992 – The inhibitory effect of the combination of antineoplaston A-10 injection with a small dose of cis-diamminedichloroplatinum on cell and tumor growth of human hepatocellular carcinoma
H TSUDA, et al (Japan)
The Inhibitory Effect of the Combination of Antineoplaston A-10 Injection with a Small Dose of cis-Diamminedichloroplatinum on Cell and Tumor Growth of Human Hepatocellular Carcinoma
Jpn J Cancer Res. 1992 May;83(5):527-31
Jpn. J. Cancer Res. 83, 527-531
Jpn J Cancer Res. 1992 May;83 (5):527-31;jsessionid=4ECD3F595A3971B5AB87763862867844.d03t02?v=1&t=hbmd55gj&s=a14b626a37db3ecd558109cee30dfe26c71827763862867844
Jpn J Cancer Res 83 (5):527-31 (1992)
Department of Anesthesiology, Kurume University, School of Medicine, Fukuoka-ken
Article first published online: 26 AUG 2005
DOI: 10.1111/j.1349-7006.1992.tb01960.x
Japan Journal Cancer Research
Cancer Science, Wiley Online Library
Volume 83, Issue 5, pages 527–531, May 1992
Burzynski References: 1, 4 – 7 and 9
Nishida (Japan) A-10 Reference: 2
11/15/1995 – Sodium PHENYLACETATE Induces Growth Inhibition and Bcl-2 Down-Regulation and Apoptosis in MCF7ras Cells in Vitro and in nude mice
Cancer Res. 1995 Nov 15;55(22):5156-60.

Click to access 5156.full.pdf

Institut d’Oncologie Moléculaire et Cellulaire Humaine, Bobigny, France.
1. SAMID, D., Shac, S., and Sherman, L. T. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res., 52: 1988-1992, 1992
9/2001 – Sodium PHENYLACETATE enhances the inhibitory effect of dextran derivative on breast cancer cell growth in vitro and in nude mice
Br J Cancer. 2001 September; 85(6): 917–923.
doi: 10.1054/bjoc.2001.1993
PMCID: PMC2375080
3/2005 Effects of antineoplaston AS2-1 against post-operative lung metastasis in orthotopically implanted colon cancer in nude rat
Hideaki TSUDA
Oncol Rep. 2005 Mar; 13 (3):389-95
Oncol Rep 13 (3): 389-95 (2005)
Oncology Reports, 3/2005, Volume 13 Number 3
Pages: 389-395 Oncology Reports, Spandidos Publications
Department of Surgery, Kurume University School of Medicine, Kurume City, Fukuoka, Japan
7 – 8/27/2007 Induction of apoptosis in human hepatocellular carcinoma cells by synthetic antineoplaston A10
Induction of Apoptosis in Human Hepatocellular Carcinoma Cells by Synthetic Antineoplaston A10
Anticancer Res. 2007 Jul-Aug;27(4B):2427-31
Anticancer Res 27(4B):2427-31 (2007)
Anticancer Res. 7 – 8/2007; 27(4B):2427-31

Click to access 2427.full.pdf

Anticancer Research, Vol. 27, No. 4B, 2007, pp. 2427-2431
Anticancer Research
HighWire Press
School of Pharmaceutical Sciences, Shandong University, Jinan, Japan
International Journal of Cancer Treatment
Burzynski References: 1, 3, 5, 13 and 15
Badria (Egypt) A-10 References: 2 and 20
Wang A10 Reference: 4


Adam L, Crépin M, Savin C, Israël L. Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7ras cells in vitro and in nude mice. Cancer Res. 1995 Nov 15;55(22):5156–5160.

Shack S, Miller A, Liu L, Prasanna P, Thibault A, SAMID D. Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate. Clin Cancer Res. 1996 May;2(5):865–872.

SAMID D, Shack S, Myers CE. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest. 1993 May;91(5):2288–2295.

SAMID D, Hudgins WR, Shack S, Liu L, Prasanna P, Myers CE. Phenylacetate and Phenylbutyrate as novel, nontoxic differentiation inducers. Adv Exp Med Biol. 1997;400A:501–505.

SAMID D, Wells M, Greene ME, Shen W, Palmer CN, Thibault A. Peroxisome proliferator-activated receptor gamma as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity. Clin Cancer Res. 2000 Mar;6(3):933–941.

Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, Weinberger MS, Headlee DJ, McCall NA, SAMID D, et al. A phase I and pharmacokinetic study of intravenous phenylacetate
in patients with cancer. Cancer Res. 1994 Apr 1;54(7):1690–1694.
3/2005 – Effects of antineoplaston AS2-1 against post-operative lung metastasis in orthotopically implanted colon cancer in nude rat.
Matono K, Ogata Y, Tsuda H, Araki Y, Shirouzu K.
Oncol Rep. 2005 Mar;13(3):389-95
Oncology Reports
March 2005
Volume 13 Number 3
Department of Surgery, Kurume University School of Medicine, Kurume City, Fukuoka, Japan
(former web-site screenshots)

Click to access burzynski_fdauntitled_promo_2012.pdf

Stanislaw Rajmund Burzynski Publications: